tradingkey.logo
tradingkey.logo
検索

Harvard Bioscience Inc

HBIO
ウォッチリストに追加
6.050USD
-0.100-1.63%
終値 07/01, 16:00ET15分遅れの株価
27.29M時価総額
損失額直近12ヶ月PER

詳細情報 Harvard Bioscience Inc 企業名

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Harvard Bioscience Incの企業情報

企業コードHBIO
会社名Harvard Bioscience Inc
上場日Oct 21, 2013
最高経営責任者「CEO」Duke (John D)
従業員数330
証券種類Ordinary Share
決算期末Oct 21
本社所在地84 October Hill Rd
都市HOLLISTON
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号01746-1371
電話番号15088938999
ウェブサイトhttps://www.harvardbioscience.com/
企業コードHBIO
上場日Oct 21, 2013
最高経営責任者「CEO」Duke (John D)

Harvard Bioscience Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

よくある質問

Harvard Bioscience Incの上位5名の株主は誰ですか?

Harvard Bioscience Incの上位5名の株主は以下のとおりです。Ms. Katherine Anne Eade, J.D.

Harvard Bioscience Inc(HBIO)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Harvard Bioscience Incの株式を保有している機関は201社あり、保有株式の総市場価値は約2.44Mで、全体の54.17%を占めています。2025Q4と比較して、機関の持ち株は-447956.00増加しています。

Harvard Bioscience Incの最大の収益源は何ですか?

2026Q1において、Instruments, equipment, software and accessories部門がHarvard Bioscience Incにとって最大の収益を生み出しており、その金額は78.26Mで、全収益の90.42%を占めています。